Lineage Cell Therapeutics Statistics
Total Valuation
LCTX has a market cap or net worth of $448.31 million. The enterprise value is $394.94 million.
Important Dates
The last earnings date was Thursday, March 5, 2026, after market close.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LCTX has 242.33 million shares outstanding. The number of shares has increased by 14.95% in one year.
| Current Share Class | 242.33M |
| Shares Outstanding | 242.33M |
| Shares Change (YoY) | +14.95% |
| Shares Change (QoQ) | +3.63% |
| Owned by Insiders (%) | 5.13% |
| Owned by Institutions (%) | 21.72% |
| Float | 180.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.80 |
| Forward PS | 23.88 |
| PB Ratio | 10.10 |
| P/TBV Ratio | 205.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 27.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.20, with a Debt / Equity ratio of 0.06.
| Current Ratio | 5.20 |
| Quick Ratio | 4.99 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -105.30% and return on invested capital (ROIC) is -21.73%.
| Return on Equity (ROE) | -105.30% |
| Return on Assets (ROA) | -12.06% |
| Return on Invested Capital (ROIC) | -21.73% |
| Return on Capital Employed (ROCE) | -21.52% |
| Weighted Average Cost of Capital (WACC) | 13.84% |
| Revenue Per Employee | $189,039 |
| Profits Per Employee | -$825,104 |
| Employee Count | 77 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5.28M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +256.32% in the last 52 weeks. The beta is 1.76, so LCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.76 |
| 52-Week Price Change | +256.32% |
| 50-Day Moving Average | 1.72 |
| 200-Day Moving Average | 1.42 |
| Relative Strength Index (RSI) | 53.66 |
| Average Volume (20 Days) | 1,159,425 |
Short Selling Information
The latest short interest is 25.19 million, so 10.40% of the outstanding shares have been sold short.
| Short Interest | 25.19M |
| Short Previous Month | 25.10M |
| Short % of Shares Out | 10.40% |
| Short % of Float | 13.97% |
| Short Ratio (days to cover) | 21.89 |
Income Statement
In the last 12 months, LCTX had revenue of $14.56 million and -$63.53 million in losses. Loss per share was -$0.28.
| Revenue | 14.56M |
| Gross Profit | 14.41M |
| Operating Income | -21.78M |
| Pretax Income | -68.65M |
| Net Income | -63.53M |
| EBITDA | -21.08M |
| EBIT | -21.78M |
| Loss Per Share | -$0.28 |
Full Income StatementBalance Sheet
The company has $55.78 million in cash and $2.42 million in debt, with a net cash position of $53.36 million or $0.22 per share.
| Cash & Cash Equivalents | 55.78M |
| Total Debt | 2.42M |
| Net Cash | 53.36M |
| Net Cash Per Share | $0.22 |
| Equity (Book Value) | 43.35M |
| Book Value Per Share | 0.18 |
| Working Capital | 47.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.92 million and capital expenditures -$522,000, giving a free cash flow of -$19.44 million.
| Operating Cash Flow | -18.92M |
| Capital Expenditures | -522,000 |
| Free Cash Flow | -19.44M |
| FCF Per Share | -$0.08 |
Full Cash Flow StatementMargins
| Gross Margin | 99.00% |
| Operating Margin | -149.62% |
| Pretax Margin | -471.61% |
| Profit Margin | n/a |
| EBITDA Margin | -144.82% |
| EBIT Margin | -149.62% |
| FCF Margin | n/a |
Dividends & Yields
LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.95% |
| Shareholder Yield | -14.95% |
| Earnings Yield | -14.17% |
| FCF Yield | -4.34% |
Analyst Forecast
The average price target for LCTX is $5.00, which is 170.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.00 |
| Price Target Difference | 170.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 61.81% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 31, 1997. It was a forward split with a ratio of 3:1.
| Last Split Date | Oct 31, 1997 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
